Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Name
As of 11/19/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
YTD Return
-29.1%
1 yr return
-17.5%
3 Yr Avg Return
-30.1%
5 Yr Avg Return
-5.9%
Net Assets
$1.87 B
Holdings in Top 10
53.6%
Expense Ratio 0.75%
Front Load N/A
Deferred Load N/A
Turnover N/A
Redemption Fee N/A
Standard (Taxable)
N/A
IRA
N/A
Fund Type
Exchange Traded Fund
Name
As of 11/19/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
The Fund is an actively-managed exchange-traded fund (“ETF”) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics* revolution (“Genomics Revolution Companies”), which is described below:
• Genomic Revolution Companies. Companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing,** analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics,*** molecular medicine and agricultural biotechnology.
In selecting companies that the Adviser believes are relevant to a particular investment theme, the Adviser seeks to identify, using its own internal research and analysis, companies capitalizing on disruptive innovation or that are enabling the further development of a theme in the markets in which they operate. The Adviser’s internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment themes and identify and take advantage of trends that have ramifications for individual companies or entire industries. The Adviser’s process for identifying Genomic Revolution Companies uses both “top down” (thematic research sizing the potential total available market, and surfacing the prime beneficiaries) and “bottom up” (valuation, fundamental and quantitative measures) approaches. In both the Adviser’s “top down” and “bottom up” approaches, the Adviser evaluates environmental, social, and governance (“ESG”) considerations. In its “top down” approach, the Adviser uses the framework of the United Nations Sustainable Development Goals to integrate ESG considerations into its research and investment process. The Adviser, however, does not use ESG considerations to limit, restrict or otherwise exclude companies or sectors from the Fund’s investment universe. In its “bottom up” approach, the Adviser makes its investment decisions primarily based on its analysis of the potential of individual companies, while integrating ESG considerations into that process. The Adviser’s highest-conviction investment ideas are those that it believes present the best risk-reward opportunities. The Fund may invest in certain companies that the Adviser believes are well-positioned to capitalize on and expected to devote substantial efforts to business lines enabled by disruptive genomic innovation, even if such companies do not currently derive a substantial portion of their revenues from genomics related activities.
Under normal circumstances, substantially all of the Fund’s assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Fund’s investments will include micro-, small-, medium- and large-capitalization companies. The Fund’s investments in foreign equity securities will be in both developed and emerging markets.
* The Adviser defines “genomics” as the study of genes and their functions, and related techniques (e.g., genomic sequencing).
** The Adviser uses the term “genomic sequencing” to refer to techniques that allow researchers to read and decipher the genetic information found in the DNA (i.e., the exact sequence of bases A, C, G and T in a DNA molecule), including the DNA of bacteria, plants, animals and human beings.
*** The Adviser defines “bioinformatics” as the science of collecting and analyzing complex biological data such as genetic codes.
The Fund will be concentrated (i.e., more than 25% of the value of the Fund’s assets) in securities of issuers having their principal business activities in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. Other industries in the health care sector include medical laboratories and research and drug manufacturers. The Fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (“ADRs”) and Global Depositary Receipts (“GDRs”).
The Fund is classified as a “non-diversified” investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), which means that it may invest a high percentage of its assets in a limited number of issuers.
Period | ARKG Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -29.1% | -29.1% | 19.1% | 100.00% |
1 Yr | -17.5% | -17.5% | 44.4% | 100.00% |
3 Yr | -30.1%* | -30.1% | 8.6% | 100.00% |
5 Yr | -5.9%* | -7.8% | 11.8% | 98.63% |
10 Yr | 2.4%* | 0.0% | 13.1% | 97.30% |
* Annualized
Period | ARKG Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 16.2% | -12.6% | 19.0% | 6.92% |
2022 | -53.9% | -53.9% | 3.2% | 100.00% |
2021 | -34.3% | -39.6% | 24.2% | 99.34% |
2020 | 178.2% | -13.6% | 178.2% | 0.67% |
2019 | 39.8% | 3.8% | 63.8% | 5.26% |
Period | ARKG Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -29.1% | -29.1% | 19.1% | 100.00% |
1 Yr | -17.5% | -17.5% | 44.4% | 100.00% |
3 Yr | -30.1%* | -30.1% | 8.6% | 100.00% |
5 Yr | -5.9%* | -7.8% | 11.8% | 98.63% |
10 Yr | 2.4%* | 0.0% | 13.1% | 97.30% |
* Annualized
Period | ARKG Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 16.2% | -12.6% | 19.0% | 6.92% |
2022 | -53.9% | -53.9% | 3.7% | 100.00% |
2021 | -33.9% | -33.9% | 26.0% | 100.00% |
2020 | 180.6% | -0.7% | 180.6% | 0.67% |
2019 | 44.1% | 4.6% | 63.8% | 5.26% |
ARKG | Category Low | Category High | ARKG % Rank | |
---|---|---|---|---|
Net Assets | 1.87 B | 6.66 M | 45.7 B | 22.01% |
Number of Holdings | 41 | 25 | 430 | 89.31% |
Net Assets in Top 10 | 784 M | 2.12 M | 22.1 B | 32.08% |
Weighting of Top 10 | 53.60% | 18.4% | 79.7% | 23.27% |
Weighting | Return Low | Return High | ARKG % Rank | |
---|---|---|---|---|
Stocks | 99.39% | 87.34% | 106.13% | 22.64% |
Cash | 0.61% | 0.00% | 33.01% | 74.84% |
Preferred Stocks | 0.00% | 0.00% | 7.86% | 64.15% |
Other | 0.00% | -22.99% | 23.24% | 64.78% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 48.70% |
Bonds | 0.00% | 0.00% | 12.39% | 61.64% |
Weighting | Return Low | Return High | ARKG % Rank | |
---|---|---|---|---|
Healthcare | 96.76% | 59.26% | 100.00% | 88.96% |
Technology | 2.17% | 0.00% | 22.69% | 1.95% |
Financial Services | 0.89% | 0.00% | 1.60% | 5.19% |
Basic Materials | 0.19% | 0.00% | 7.16% | 29.87% |
Utilities | 0.00% | 0.00% | 0.00% | 44.81% |
Real Estate | 0.00% | 0.00% | 5.89% | 47.40% |
Industrials | 0.00% | 0.00% | 7.02% | 48.70% |
Energy | 0.00% | 0.00% | 0.00% | 44.81% |
Communication Services | 0.00% | 0.00% | 9.11% | 48.05% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 51.95% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 47.40% |
Weighting | Return Low | Return High | ARKG % Rank | |
---|---|---|---|---|
US | 99.39% | 66.06% | 104.41% | 17.61% |
Non US | 0.00% | 0.00% | 28.87% | 84.91% |
ARKG Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 0.75% | 0.08% | 4.48% | 73.58% |
Management Fee | 0.75% | 0.03% | 1.25% | 61.64% |
12b-1 Fee | 0.00% | 0.00% | 1.00% | 9.09% |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
ARKG Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 1.00% | N/A |
ARKG Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
ARKG Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | N/A | 0.00% | 238.00% | 74.55% |
ARKG | Category Low | Category High | ARKG % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.24% | 64.15% |
ARKG | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | None | Annual | Annual | Annual |
ARKG | Category Low | Category High | ARKG % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.28% | -2.54% | 1.85% | 53.29% |
ARKG | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Date | Amount | Type |
---|---|---|
Dec 29, 2021 | $0.382 | OrdinaryDividend |
Dec 29, 2020 | $0.790 | OrdinaryDividend |
Dec 27, 2019 | $1.054 | CapitalGainShortTerm |
Dec 27, 2018 | $0.196 | CapitalGainShortTerm |
Dec 27, 2018 | $0.270 | CapitalGainLongTerm |
Dec 27, 2017 | $0.193 | CapitalGainShortTerm |
Dec 27, 2017 | $0.135 | CapitalGainLongTerm |
Start Date
Tenure
Tenure Rank
Oct 30, 2014
7.59
7.6%
Cathie registered ARK Investment Management LLC (“ARK”) as an investment adviser with the U.S. Securities and Exchange Commission in January 2014. Prior to ARK, Cathie spent twelve years at AllianceBernstein as Chief Investment Officer of Global Thematic Strategies where she managed $5 billion. Cathie joined Alliance Capital from Tupelo Capital Management, a hedge fund she co-founded which, in 2000, managed $800 million in global thematic strategies. Prior to her tenure at Tupelo Capital, she worked for 18 years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. She started her career in Los Angeles, California at The Capital Group as an Assistant Economist. Cathie received her Bachelor of Science, summa cum laude, in Finance and Economics from the University of Southern California in 1981. In 2016, Cathie received the “Women in Finance – Outstanding Contribution Award” from Market Media.
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.88 | 0.25 |
Dividend Investing Ideas Center
Have you ever wished for the safety of bonds, but the return potential...
Dividend Investing Ideas Center
If you are reaching retirement age, there is a good chance that you...
Dividend Investing Ideas Center
If you are reaching retirement age, there is a good chance that you...